secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2023-01-27T23:59:59+00:00
Accession:  0001516551-23-000016
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience faces $4.85M jury verdict in wrongful termination case; amends Verdeilite sale terms
--------------------------------------------------------------------------------

- Jury awards Wendy Cunning $512,500 economic, $840,960 non-economic, and $3.5M punitive damages; company plans to appeal.
- Amendment to Verdeilite stock purchase agreement reduces purchase price by ~$30k and adjusts payment terms to 5 monthly installments starting Dec 31, 2023.
- Buyer must use best efforts to obtain ~$123k C3 Excise Bond refund from Canada Revenue Agency and remit to Emerald Health.
- Exhibit shows total purchase consideration remains ~CAD$12.71M, with deferred payments bearing interest up to Prime +5.55%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000016/0001516551-23-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000016/skye-20230126.htm
  HTML page:      https://secwatch.observer/filing/0001516551-23-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer